BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34590580)

  • 1. Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion.
    Harada A; Matsumoto S; Yasumizu Y; Shojima K; Akama T; Eguchi H; Kikuchi A
    Elife; 2021 Sep; 10():. PubMed ID: 34590580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target.
    Fujii S; Matsumoto S; Nojima S; Morii E; Kikuchi A
    Oncogene; 2015 Sep; 34(37):4834-44. PubMed ID: 25486429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
    Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
    J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma.
    Fujii S; Shinjo K; Matsumoto S; Harada T; Nojima S; Sato S; Usami Y; Toyosawa S; Morii E; Kondo Y; Kikuchi A
    Oncotarget; 2016 Dec; 7(49):81571-81587. PubMed ID: 27835592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth.
    Harada T; Matsumoto S; Hirota S; Kimura H; Fujii S; Kasahara Y; Gon H; Yoshida T; Itoh T; Haraguchi N; Mizushima T; Noda T; Eguchi H; Nojima S; Morii E; Fukumoto T; Obika S; Kikuchi A
    Mol Cancer Ther; 2019 Mar; 18(3):602-612. PubMed ID: 30647122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer.
    Hu Q; Masuda T; Sato K; Tobo T; Nambara S; Kidogami S; Hayashi N; Kuroda Y; Ito S; Eguchi H; Saeki H; Oki E; Maehara Y; Mimori K
    Ann Surg Oncol; 2018 Mar; 25(3):745-753. PubMed ID: 29270876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARL4C might serve as a prognostic factor and a novel therapeutic target for gastric cancer: bioinformatics analyses and biological experiments.
    Xie N; Bai Y; Qiao L; Bai Y; Wu J; Li Y; Jiang M; Xu B; Ni Z; Yuan T; Shi Y; Wu K; Xu F; Wang J; Dong L; Liu N
    J Cell Mol Med; 2021 Apr; 25(8):4014-4027. PubMed ID: 33724652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
    Kimura K; Matsumoto S; Harada T; Morii E; Nagatomo I; Shintani Y; Kikuchi A
    Cancer Sci; 2020 Mar; 111(3):951-961. PubMed ID: 31925985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; CaƱamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARF6 and AMAP1 are major targets of
    Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
    Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
    Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
    Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells.
    Assi M; Achouri Y; Loriot A; Dauguet N; Dahou H; Baldan J; Libert M; Fain JS; Guerra C; Bouwens L; Barbacid M; Lemaigre FP; Jacquemin P
    Cancer Res; 2021 May; 81(10):2679-2689. PubMed ID: 33602788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic significance of Arl4c expression in colorectal cancer.
    Chen X; Su Z; Wang S; Xu H
    Cancer Biomark; 2016; 16(2):253-7. PubMed ID: 26756615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.